Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2010
06/22/2010US7741080 elucidate the functional mechanism of adipocyte hypertrophy-dependent suppression of adiponectin production; identifies factors that can increase the expression of adiponectin gene; provides adiponectin expression-inducing agents; metabolic or heart diseases
06/22/2010US7741078 Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same
06/22/2010US7741077 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
06/22/2010US7741076 developing genetic constructs capable of expressing lipidated rP6 in e coli; used for to preventing disease caused by Haemophilus influenzae
06/22/2010US7741072 Polypeptide variants
06/22/2010US7741064 biological reagents comprising the GPCR oligomers, methods of producing said biological reagents and assays for determining their function; determining compounds that have the ability to modulate the function of GPCR oligomers
06/22/2010US7741056 Junctional Adhesion Molecule (JAM); treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer; antagonist of a native sequence STIgMA polypeptide
06/22/2010US7741051 a fragment derived from the MET ectodomain in monomer form binds to hepatocyte growth factor/scatter factor (HGF/SF) either in the presence or absence of heparin; method for determining whether an agent binds to a MET ectodomain fragment in monomeric form
06/22/2010US7741050 autoantibodies which recognize extracellular structures of G protein-coupled receptors; autoimmune diseases; Raynaud's syndrome, cardiomyopathy, myocarditis, hypertension
06/22/2010US7741039 Postweaning multisystemic wasting syndrome virus from pigs
06/22/2010US7741025 Method of diagnosing lung cancer using BGS42
06/22/2010US7741022 Protein inhibitor of Ran activity and methods of use thereof
06/22/2010US7740889 produced by Paenibacillus polymyxa strain; for use in therapeutic feeds, reducing levels of colonization by target bacteria in poultry
06/22/2010US7740884 Freeze-dried FSH/LH formulations
06/22/2010US7740882 polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability
06/22/2010US7740870 Group B Streptococcus antigens and corresponding DNA fragments
06/22/2010US7740862 N-glycosylated at 0, 1, 2, 3, 4, 5 or 6 asparagine residues of mutant follicle stimulating hormone; increased glycosylation and longer half-lives; for inducing ovarian hyperstimulation in a mammal; fertilization therapies
06/22/2010US7740857 Administering an isolated peptide; variants, derivatives or structural equivalents of cupredoxins or cytochrome
06/22/2010US7740856 Effect of BST2 on inflammation
06/22/2010US7740853 Fcepsilon-pe chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same
06/22/2010US7740840 High activity mutants of butyrylcholinesterase for cocaine hydrolysis
06/22/2010US7740839 Extracellular superoxide dismutase (EC SOD); fusion proteins; tat domains; cosmetics; skin disorders
06/22/2010US7740834 Murine zcytor17 ligand polypeptides
06/22/2010US7740833 Therapeutic uses of chemokine variants
06/22/2010US7740830 Imaging, diagnosis and treatment of disease
06/22/2010CA2536926C Novel method for synthesizing esters of n-[(s)-1-carboxybutyl]-(s)-alanine and use thereof for synthesizing perindopril
06/22/2010CA2518746C Method and compositions for improving animal health
06/22/2010CA2441398C Lipid lowering biphenylcarboxamides
06/22/2010CA2420996C Substituted heterocyclic compounds for treating multidrug resistance
06/22/2010CA2401655C Cardioprotective phosphonates and malonates
06/22/2010CA2384059C Method of treating cancer using tetraethyl thiuram disulfide
06/22/2010CA2374346C Inhibitors of memapsin 2 and use thereof
06/22/2010CA2295577C Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumors originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma
06/22/2010CA2265480C Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (hnf) 1 alpha (.alpha.), hnf-1.beta. and hnf-4.alpha.
06/22/2010CA2256483C P13 lipid kinase
06/22/2010CA2216963C Tie-2 ligands, methods of making and uses thereof
06/22/2010CA2211413C Human dnase i variants
06/22/2010CA2190943C Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
06/22/2010CA2175893C Protein tyrosine kinases named rse
06/22/2010CA2134380C Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
06/22/2010CA2122745C Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
06/17/2010WO2010068917A2 Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis
06/17/2010WO2010068907A2 Compositions of proton pump inhibitors and insulin secretagogues, kits and methods of their use to treat diabetes
06/17/2010WO2010068861A1 Crystalline forms of genistein
06/17/2010WO2010068817A1 Glycan-specific analytical tools
06/17/2010WO2010068735A1 Pharmaceutical compositions
06/17/2010WO2010068714A2 Deuterated compounds as hepatitis c virus (hcv) inhibitors
06/17/2010WO2010068692A1 Cell-permeant peptide-based inhibitor of kinases
06/17/2010WO2010068684A2 Methods and compositions for specific modulation of mcl-1
06/17/2010WO2010068414A2 Methods for treating obesity related disease
06/17/2010WO2010067918A1 Apoptosis-inducing composition containing elafin, and preparation method thereof
06/17/2010WO2010067915A1 Composition comprising expression or activity inhibitors of ninjurin 1 for the prevention and treatment of inflammatory disease
06/17/2010WO2010067882A1 Pharmaceutical composition for treatment of cancer and asthma
06/17/2010WO2010067339A2 Fusion protein capable of binding vegf-a and tnf-alpha
06/17/2010WO2010066636A1 Novel insulin analogues
06/17/2010WO2010066326A1 Combination of insulin with triazine derivatives and its use for treating diabetes
06/17/2010WO2010066125A1 A short peptide, preparation and uses thereof
06/17/2010WO2010066090A1 Fusion proteins of apoptin-protein transduction domian of carboxyl-terminal end of ec-sod
06/17/2010WO2010066062A1 Basic fsh fraction for use as a cell-proliferation-controlling agent
06/17/2010WO2010066046A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
06/17/2010WO2010066018A1 Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer
06/17/2010WO2010066010A1 Process for the preparation of asymmetrical bis(thiosemicarbazones)
06/17/2010WO2010065995A1 Isolated vegf-c and vegf-d peptides and uses thereof
06/17/2010WO2010044919A3 Smallpox dna vaccine and the antigens therein that elicit an immune response
06/17/2010WO2010043566A3 Combination of an insulin and a glp-1 agonist
06/17/2010WO2010042747A3 Fgf21 mutants and uses thereof
06/17/2010WO2010040054A3 Methods for suppressing toll-like receptor activity
06/17/2010WO2010031801A3 Composition and methods for modulating toll-like receptor activity
06/17/2010WO2010031043A3 Reducing or preventing neuroinflammation or neurotoxicity
06/17/2010WO2010029104A3 Use of a pharmaceutical composition for the local treatment of infections, and medical product
06/17/2010WO2010007168A3 Treatment of rheumatoid arthritis with mammal beta defensins
06/17/2010WO2009158480A3 Stimulation of cartilage formation using reduced pressure treatment and chondrocytes
06/17/2010WO2009142773A8 Multivalent fibronectin based scaffold domain proteins
06/17/2010WO2009140972A3 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
06/17/2010WO2009120082A3 Means and methods for influencing electrical activity of cells
06/17/2010US20100152863 Bioactive Grafts and Composites
06/17/2010US20100152649 Apparatus and method for transdermal delivery of parathyroid hormone agents
06/17/2010US20100152130 Treatment of cancer with glutamine
06/17/2010US20100152120 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
06/17/2010US20100152119 Pharmaceutical and/or cosmetic composition containing peptides
06/17/2010US20100152118 Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
06/17/2010US20100152117 Aequorin-Containing Compositions and Methods of Using Same
06/17/2010US20100152116 Treatment of amyotrophic lateral sclerosis
06/17/2010US20100152115 Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
06/17/2010US20100152114 Antioxidant activity of GH-RH Antagonists
06/17/2010US20100152113 Metal-binding therapeutic peptides
06/17/2010US20100152112 Quinoline derivatives as p13 kinase inhibitors
06/17/2010US20100152111 Polymer-based sustained release device
06/17/2010US20100152110 Alternate reading frame polypeptides derived from hepatitis c and methods of their use
06/17/2010US20100152109 Influenza inhibiting compositions and methods
06/17/2010US20100152108 Methods and combination therapies for treating alzheimer's disease
06/17/2010US20100152107 Long-term feed - cancer patient
06/17/2010US20100152106 Agent for therapy and/or improvement of disseminated intravascular coagulation
06/17/2010US20100152105 Use of rapamycin derivatives in chronic rejection
06/17/2010US20100152104 Methods for Inhibiting Growth of Prolactin-Responsive Cancer Cells with Cyclosporine A or Other Cyclophilin Inhibitors
06/17/2010US20100152103 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
06/17/2010US20100152102 Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women
06/17/2010US20100152101 Triazol compounds for treating biofilm formation
06/17/2010US20100152100 Accelerated therapy
06/17/2010US20100152099 Macrocyclic compounds for inhibition of tumor necrosis factor alpha
1 ... 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 ... 3163